The factor 2.4 = 0.0034(iron content of Hb in %) × 0.07(blood volume as % of body weight) × 1000. 500mg represents average iron stores.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Calculation of total iron requirement in patients with Iron Deficiency Anemia (IDA).
Planning parenteral (IV) iron replacement therapy when oral iron is ineffective, not tolerated, or rapid replenishment is required.
Second or third trimester anemia where Hb < 10.5–11.0 g/dL and ferritin < 30 ng/mL.
Pre-operative optimization for patients with scheduled Cesarean sections and known anemia.
Clinical Thresholds in Pregnancy
Iron deficiency is typically defined as Ferritin < 30 ng/mL. In the presence of inflammation (elevated CRP), a threshold of < 100 ng/mL may be used, though this is less specific in the obstetric population.
Section 2
Formula & Logic
The Ganzoni Formula
Total Iron Deficit (mg) = Body Weight (kg) × (Target Hb - Actual Hb) (g/dL) × 0.24 + Iron Stores (mg)
Parameter Definitions
Target Hb
Typically 15 g/dL (standard Ganzoni) or 12 g/dL (Obstetric modification)
Factor 0.24
0.0034 (Fe content of Hb ≈0.34%) × 0.07 (Blood vol ≈7% of weight) × 1000
Iron Stores
500 mg (if weight > 35 kg)
Weight Selection in Pregnancy
Use pre-pregnancy weight for the calculation. Using actual weight in late pregnancy may lead to iron overestimation/overload due to the significant portion of weight attributed to fetal/placental tissue and edema.
Section 3
Pearls/Pitfalls
Obstetric Considerations
IV iron is generally avoided in the 1st trimester (limited safety data); it is preferred in the 2nd and 3rd trimesters.
In pregnancy, many clinicians use a Target Hb of 12 g/dL rather than the 15 g/dL used in the original formula to avoid over-replacement.
The formula accounts for the "Iron Stores" depot (500mg), which is essential to prevent immediate recurrence of anemia after Hb correction.
Limitations
The Ganzoni formula is known to underestimate requirements in some populations; simplified dosing (e.g., 1000mg flat dose) is increasingly used for newer formulations.
Does not account for ongoing blood loss (e.g., placenta previa or GI bleeds).
Formula does not apply to non-iron deficiency anemias (e.g., B12 deficiency, Thalassemia).
Section 4
Next Steps
Administration Strategy
01
Verify Iron Deficiency: Confirm Ferritin < 30 ng/mL or Transferrin Saturation (TSAT) < 20%.
02
Select Formulation: Choose based on local formulary (e.g., Iron Sucrose, Ferric Carboxymaltose).
03
Dosing Schedule: If total deficit > maximum single dose (e.g., >1000mg for FCM), split into two sessions 7 days apart.
04
Monitoring: Recheck CBC and Ferritin 4–8 weeks post-infusion. Do not recheck within 2 weeks of infusion.
Safety Warning
Resuscitation equipment and trained staff must be available during infusions due to the risk (though rare with modern formulations) of hypersensitivity or anaphylactoid reactions.
Section 5
Evidence Appraisal
Primary Reference
Intravenous iron-dextran: therapeutic and experimental possibilities.
Ganzoni AM. • Schweiz Med Wochenschr.. 1970;Original derivation of the formula (100:1187-91).
Obstetric Validation
Intravenous iron sucrose v/s oral ferrous fumarate in treatment of anemia in pregnancy.
Bhavi SB et al. • J Obstet Gynaecol India.. 2017;Clinical study utilizing Ganzoni-calculated doses to demonstrate safety and superior efficacy of IV replacement in the third trimester.
Section 6
Literature
Dr. Andreas M. Ganzoni
A Swiss hematologist who sought to provide a physiological basis for iron replacement. Before this formula, IV iron dosing was largely empirical and frequently resulted in either ineffective treatment or unnecessary toxicity.
Historical Context
The Ganzoni formula was developed in an era where Iron Dextran was the primary IV option. While newer compounds (like Ferric Carboxymaltose) have modified dosing logic, the Ganzoni equation remains the academic gold standard for calculating total body iron deficit.
